Cargando…
Upregulation of MUC1 by its novel activator 14-3-3ζ promotes tumor invasion and indicates poor prognosis in lung adenocarcinoma
Lung adenocarcinoma (LAC) is currently the predominant histological subtype of lung cancer. Despite recent advancement in targeted therapies, the average 5-year survival rate is only 15%, highlighting the need to identify previously unrecognized molecular events that propel cancer development. Herei...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780016/ https://www.ncbi.nlm.nih.gov/pubmed/28901525 http://dx.doi.org/10.3892/or.2017.5948 |
Sumario: | Lung adenocarcinoma (LAC) is currently the predominant histological subtype of lung cancer. Despite recent advancement in targeted therapies, the average 5-year survival rate is only 15%, highlighting the need to identify previously unrecognized molecular events that propel cancer development. Herein, we showed knockdown of 14-3-3ζ suppresses cell proliferation, migration and invasion capability of A549 and H1299 cells. MUC1 was then identified as a novel target of 14-3-3ζ protein. Overexpression of MUC1 is found to induce epithelial-mesenchymal transition and promote metastasis of lung cancer cells, while knockdown of 14-3-3ζ can completely abolish the oncogenic function of MUC1.Furthermore, we unraveled a novel mechanism that 14-3-3ζ activates NF-κB signaling pathway, and therefore enhanced MUC1/NF-κB feedback loop to upregulate MUC1 expression. From a clinical point of view, we evaluated the expression of14-3-3ζ and MUC1 in GSE68465 datasets, in which high expression of14-3-3ζ and MUC1 emerged as poor prognostic factors in LAC patients. In conclusion, we provide novel evidence that 14-3-3ζ regulates MUC1 through MUC1/NF-κB feedback loop. 14-3-3ζ and MUC1 is a promising prognostic biomarker for lung cancer patients and therapeutic targeting of 14-3-3ζ and MUC1 may be a potential treatment option for patients with LAC. |
---|